Quantifying the World's Clinical Trial Efficacy, Tolerability, and Safety Information to Enable Good Drug Development Decisions

Cardiovascular Diseases

Quantitative Solutions has done extensive work in the cardiovascular therapeutic area.

The following links show an example of the work on the design of an adaptive Phase II dose finding study for a novel factor Xa inhibitor:
QX Workshop
Paper on Factor Xa Inhibitor

The following article describes model based development of a new lipid-altering agent, Gemcabene, based on the analysis of publicly available summary-level data and proprietary patient-level data. Paper on lipid-altering agent